Evaluation of the Case-Crossover (CCO) Study Design for Adverse Drug Event Detection.
Zachary BurninghamTao HeChia-Chen TengXi ZhouJonathan NebekerBrian C SauerPublished in: Drug safety (2018)
The CCO performed best for acute-onset outcomes, but may be useful for exploring adverse outcomes with accumulative effects. Careful consideration must be given to the hypothesized drug exposure and outcome distribution because specification of risk and control window duration affects CCO performance.
Keyphrases
- adverse drug
- drug induced
- liver failure
- electronic health record
- emergency department
- respiratory failure
- open label
- loop mediated isothermal amplification
- label free
- randomized controlled trial
- aortic dissection
- type diabetes
- real time pcr
- placebo controlled
- insulin resistance
- weight loss
- acute respiratory distress syndrome
- sensitive detection
- breast cancer risk